A phase 2 study evaluated the use of ruxolitinib plus standard GVHD prophylaxis in patients with myelofibrosis undergoing ...
Patients with childhood and young adult cancer have an increased long-term risk for diabetes, noted as early as 10 years ...
A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “A case report of donor cell–derived ...
Fintel reports that on February 13, 2025, UBS initiated coverage of Jasper Therapeutics (NasdaqCM:JSPR) with a Buy ...
Risk factors for secondary skin cancer after blood or marrow transplant include those who had treatment with a monoclonal ...
Leaked data showed that Pfizer’s mevrometostat has strong therapeutic potential in metastatic castration-resistant prostate ...
Hematopoietic stem cell transplantation (HSCT) is a vital treatment for both malignant and non-malignant disorders in pediatric patients.
Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in untreated MCL ...
The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...
More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...
Caris Life Sciences® (Caris), a leading next-generation AI TechBio company and precision medicine pioneer, today announced ...
Dana-Farber Cancer Institute researchers will present key research studies at the 2025 Tandem Meetings, the premier ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback